03.05.2022 • NewsJohnson Matthey

Standard Industries Takes Stake in Johnson Matthey

The investment arm of US industrial group Standard Industries has taken a 5.23% stake in UK-based multinational specialty chemicals and sustainable technologies company Johnson Matthey. Neither company has commented on the transaction.

Speaking with Reuters news agency, a London-based trader said the purchase could be a prelude to “some kind of move.” Separately, Jefferies analysts said in a note that they would consider this to be “something like an ideal owner, with an ability to take a long-term view on the cash generation from the clean air business.”

Last December, Johnson Matthey agreed to sell a majority stake in its Health division to US investment company Altaris Capital Partners for an enterprise value of £325 million. The transaction is expected to close in mid-2022.

In January, the London-based company decided to close down its Battery Materials business after discussions for a sale with a number of parties failed to reach agreement.

A year ago, Standard Industries bought US global specialty chemical company W. R. Grace for about $7 billion.

Author: Elaine Burridge, Freelance Journalist

Photo by Sean Pollock on Unsplash
Photo by Sean Pollock on Unsplash

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.